WO2012083274A3 - Methods for diagnosis, prognosis and methods of treatment - Google Patents
Methods for diagnosis, prognosis and methods of treatment Download PDFInfo
- Publication number
- WO2012083274A3 WO2012083274A3 PCT/US2011/065675 US2011065675W WO2012083274A3 WO 2012083274 A3 WO2012083274 A3 WO 2012083274A3 US 2011065675 W US2011065675 W US 2011065675W WO 2012083274 A3 WO2012083274 A3 WO 2012083274A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methods
- activation
- approach
- cellular
- cell population
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57426—Specifically defined cancers leukemia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The present invention provides an approach for the determination of the activation states of a plurality of proteins in single cells. This approach permits the rapid detection of heterogeneity in a complex cell population based on activation states, expression markers and other criteria, and the identification of cellular subsets that exhibit correlated changes in activation within the cell population. Moreover, this approach allows the correlation of cellular activities or properties. In addition, the use of modulators of cellular activation allows for characterization of pathways and cell populations. The process is effective at characterizing MDS.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42391810P | 2010-12-16 | 2010-12-16 | |
US61/423,918 | 2010-12-16 | ||
US201161565935P | 2011-12-01 | 2011-12-01 | |
US61/565,935 | 2011-12-01 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2012083274A2 WO2012083274A2 (en) | 2012-06-21 |
WO2012083274A3 true WO2012083274A3 (en) | 2014-04-10 |
Family
ID=46245410
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2011/065675 WO2012083274A2 (en) | 2010-12-16 | 2011-12-16 | Methods for diagnosis, prognosis and methods of treatment |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2012083274A2 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2696402A1 (en) | 2007-08-21 | 2009-02-26 | Nodality, Inc. | Methods for diagnosis, prognosis and methods of treatment |
US8227202B2 (en) | 2008-07-10 | 2012-07-24 | Nodality, Inc. | Methods for diagnosis, prognosis and methods of treatment |
US9034257B2 (en) | 2008-10-27 | 2015-05-19 | Nodality, Inc. | High throughput flow cytometry system and method |
US9459246B2 (en) | 2009-09-08 | 2016-10-04 | Nodality, Inc. | Induced intercellular communication |
US9738933B2 (en) | 2012-12-05 | 2017-08-22 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | RNF41 as a biomarker predicting response to lenalidomide in non-del(5q) MDS |
WO2018027144A1 (en) * | 2016-08-04 | 2018-02-08 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Companion diagnostic for combination lenalidomide and erythropoietin treatment |
US11893499B2 (en) | 2019-03-12 | 2024-02-06 | International Business Machines Corporation | Deep forest model development and training |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050202451A1 (en) * | 2003-04-29 | 2005-09-15 | Burczynski Michael E. | Methods and apparatuses for diagnosing AML and MDS |
US20100009364A1 (en) * | 2008-07-10 | 2010-01-14 | Nodality, Inc. | Methods for diagnosis, prognosis and methods of treatment |
US20100240542A1 (en) * | 2009-03-23 | 2010-09-23 | Nodality, Inc. | Kits for multiparametric phospho analysis |
-
2011
- 2011-12-16 WO PCT/US2011/065675 patent/WO2012083274A2/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050202451A1 (en) * | 2003-04-29 | 2005-09-15 | Burczynski Michael E. | Methods and apparatuses for diagnosing AML and MDS |
US20100009364A1 (en) * | 2008-07-10 | 2010-01-14 | Nodality, Inc. | Methods for diagnosis, prognosis and methods of treatment |
US20100240542A1 (en) * | 2009-03-23 | 2010-09-23 | Nodality, Inc. | Kits for multiparametric phospho analysis |
Non-Patent Citations (1)
Title |
---|
KOLONICS, A. ET AL.: "Unregulated activation of STAT-5, ERK1/2 and c-Fos may contribute to the phenotypic transformation from myelodysplastic syndrome to acute leukaemia.", HAEMATOLOGIA., vol. 31, no. 2, 2001, pages 125 - 138 * |
Also Published As
Publication number | Publication date |
---|---|
WO2012083274A2 (en) | 2012-06-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2012083274A3 (en) | Methods for diagnosis, prognosis and methods of treatment | |
WO2016015058A3 (en) | Methods of determining tissues and/or cell types giving rise to cell-free dna, and methods of identifying a disease or disorder using same | |
WO2015200893A3 (en) | Methods of analyzing nucleic acids from individual cells or cell populations | |
WO2012021795A3 (en) | Pancreatic cancer biomarkers and uses thereof | |
WO2011100708A3 (en) | Assay card for sample acquisition, treatment and reaction | |
GB2568608A (en) | Personalized genetic testing | |
WO2006012507A3 (en) | Methods and compositions for risk stratification | |
WO2010045318A3 (en) | Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type | |
EP2611941A4 (en) | Gene signatures for cancer diagnosis and prognosis | |
WO2012109157A3 (en) | Bioprobes and methods of use thereof | |
EP3757225A3 (en) | Pancreatic cancer detection kit or device, and detection method | |
EP4306955A3 (en) | Integrated functional and molecular profiling of cells | |
WO2012047618A3 (en) | Mesothelioma biomarkers and uses thereof | |
WO2014028378A3 (en) | Methods and systems for detecting biological components | |
WO2012061510A3 (en) | Methods of predicting cancer cell response to therapeutic agents | |
WO2014071358A3 (en) | Novel ntrk1 fusion molecules and uses thereof | |
WO2010056945A3 (en) | Methods and systems for tissue processing and imaging | |
WO2015094996A3 (en) | Pd-l1 gene signature biomarkers of tumor response to pd-1 antagonists | |
EP4365602A3 (en) | Stomach cancer biomarker and detection method | |
BRPI0811930B8 (en) | methods and diagnostic or prognostic kit for lupus in an individual | |
WO2009032827A3 (en) | Electroporative flow cytometry | |
WO2013106844A3 (en) | Methods and compositions for the treatment and diaginosis of pancreatic cancer | |
EP2569635A4 (en) | Methods for diagnosing and treating encephalitis or epilepsy | |
WO2013028807A3 (en) | Renal cell carcinoma biomarkers and uses thereof | |
WO2015057968A3 (en) | Methods of identifying subjects responsive to treatment for an autoimmune disease and compositions for treating the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 15/10/2013) |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11849327 Country of ref document: EP Kind code of ref document: A2 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 11849327 Country of ref document: EP Kind code of ref document: A2 |